TP53 Mutations in Myeloid Neoplasms: From Clonal Hematopoiesis to Acute Leukemia
Free for members and $29 for nonmembers
This interactive live webinar is part 16 of the Emerging and Evolving Biomarkers Series.
Description:
This session will review the molecular pathogenesis of TP53 mutations in myeloid neoplasms, including the implications of the mutation in pre-malignant clonal myeloid proliferations, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The role of molecular testing and nuances in interpreting different types of TP53 mutations will be discussed. The session will also review the implications of TP53 mutation on the classification, prognosis, and prediction of treatment response of myeloid neoplasms, particularly MDS and AML.
Learning Objectives:
- Associate the presence of TP53 mutation in hematopoietic cells with diverse disease phenotypes.
- Classify the spectrum of TP53 mutations with respect to allele state, variant allele frequency, and mutation types.
- Apply the results of TP53 mutation testing to the classification and prognostic risk stratification of myeloid neoplasms, particularly myelodysplastic syndromes and acute myeloid leukemia.
Speaker:
Robert Hasserjian, MD
Massachusetts General Hospital
Moderator:
Rena Xian, MD
Johns Hopkins University
Duration: 1 Hour
Live webinar: June 20, 2024
- Click the "Access Webinar Here!" Button
- Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
- Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.
Continuing Education Credit Information
CME credit: 1.0CMLE credit: 1.0
Last day to claim credit: December 31, 2026
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This
activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education through the joint providership of American Society
for Clinical Pathology (ASCP) and Association for Molecular Pathology
(AMP). The American Society for Clinical Pathology (ASCP) is accredited
by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the
ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements
for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.